Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial [0.03%]
switches to bictegravir-lenacapavir与继续接受bictegravir-emtricitabine-tenofovir alafenamide治疗的病毒学抑制HIV-1成人患者的安全性和疗效：3期非劣效性随机对照试验
Eric G Meissner,Moti Ramgopal,Peter J Ruane et al.
Eric G Meissner et al.
Background: There is a continued need to expand the repertoire of effective single-tablet regimens to address the diverse needs of people with HIV-1. We aimed to evaluate the safety and efficacy of switching to bictegravi...
Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial [0.03%]
HIV感染者高血压的患病率、危险因素及心血管影响：REPRIEVE试验的二次分析
Esteban Martínez,Maya Watanabe,Risa Hoffman et al.
Esteban Martínez et al.
Background: People living with HIV have an increased risk of cardiovascular disease, but data on the development and consequences of hypertension remain limited. Using data from REPRIEVE, a global randomised trial of pita...
Randomized Controlled Trial
The lancet. HIV. 2026 May;13(5):e327-e337. DOI:10.1016/S2352-3018(26)00036-6 2026
The Lancet Hiv
The Lancet Hiv
Trends in incidence of HIV and other sexually transmissible infections among transgender people in Australia: a retrospective 10-year national clinical cohort study [0.03%]
澳大利亚变性人中HIV及其他性传播感染发病趋势的全国临床队列研究
Denton Callander,Teddy Cook,Jason Asselin et al.
Denton Callander et al.
Background: In Australia, transgender people have largely been excluded from public health surveillance for HIV and other sexually transmissible infections (STIs). We aimed to provide a comprehensive overview of HIV and S...
Paul Adepoju
Paul Adepoju
Danielle Giovenco,Millicent Atujuna,Don Operario et al.
Danielle Giovenco et al.
Targeted universalism for long-acting PrEP: an urgent need to avoid risk targeting and build population-level impact [0.03%]
长效PrEP的靶向普遍化：避免风险定位和产生群体层面影响的迫切需要
Laura K Beres,Sheree R Schwartz,Ronald Olum et al.
Laura K Beres et al.
New long-acting HIV prevention product choices, including lenacapavir, cabotegravir, and investigational monthly oral MK‑8527, usher in promise for ending HIV as a public health threat. Decisions taken at a product's launch determine who w...
The caveats of short-cycle antiretroviral therapy in adolescents living with HIV [0.03%]
青少年HIV感染者短期周期抗逆转录病毒治疗的局限性
Romain Palich,Jean-Jacques Parienti
Romain Palich